ACTInium-J591 Radionuclide Therapy in PSMA-Detected Metastatic HOrmone-Sensitive Recurrent Prostate CaNcer
(ACTION Trial)
Trial Summary
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but you cannot be on androgen deprivation or anti-androgen therapy to participate.
What data supports the effectiveness of the treatment Actinium-J591, Androgen Deprivation Therapy, Hormone Therapy, ADT, Stereotactic Body Radiation Therapy, Stereotactic Ablative Radiotherapy (SABR), CyberKnife?
Is the treatment Actinium-J591 safe for humans?
Research on Actinium-225, a component of Actinium-J591, shows potential for cancer treatment but highlights safety concerns due to radiotoxicity (harmful effects from radiation). In studies with mice, the treatment showed radiotoxicity at certain doses, indicating that safety depends on developing stable forms that can retain harmful byproducts.24678
How does the drug Actinium-J591 differ from other treatments for this condition?
Actinium-J591 is unique because it uses actinium-225, a radioactive substance that emits alpha particles, to target and destroy cancer cells. This approach is different from traditional treatments as it delivers radiation directly to the cancer cells, potentially reducing damage to surrounding healthy tissue.2691011
What is the purpose of this trial?
This trial is testing a new treatment that combines a special drug called Actinium-J591 with either radiation or hormone therapy. It targets patients with prostate cancer that has spread but is not clearly visible on regular scans. The drug helps make the treatments more effective by directly targeting the cancer cells.
Research Team
Himanshu Nagar, M.D.
Principal Investigator
Weill Medical College of Cornell University
Eligibility Criteria
Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive Actinium-J591 combined with radiation therapy or androgen deprivation therapy
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Actinium-J591
- Androgen Deprivation Therapy
- Stereotactic Body Radiation Therapy
Find a Clinic Near You
Who Is Running the Clinical Trial?
Weill Medical College of Cornell University
Lead Sponsor
Convergent Therapeutics, Inc.
Collaborator